具有免疫反应的新冠病毒体内模型的稳定性分析
Stability analysis in COVID-19 within-host model with immune response.
作者信息
Almocera Alexis Erich S, Quiroz Griselda, Hernandez-Vargas Esteban A
机构信息
Division of Physical Sciences and Mathematics, College of Arts and Sciences, University of the Philippines Visayas, Philippines.
Universidad Autónoma de Nuevo León, FIME, Av. Universidad S/N, Ciudad Universitaria, C.P. 66455, San Nicolás de los Garza, Nuevo León, Mexico.
出版信息
Commun Nonlinear Sci Numer Simul. 2021 Apr;95:105584. doi: 10.1016/j.cnsns.2020.105584. Epub 2020 Nov 3.
Abstract
The 2019 coronavirus disease (COVID-19) is now a global pandemic. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative pathogen of COVID-19. Here, we study an in-host model that highlights the effector T cell response to SARS-CoV-2. The stability of a unique positive equilibrium point, with viral load suggests that the virus may replicate fast enough to overcome T cell response and cause infection. This overcoming is the bifurcation point, near which the orders of magnitude for can be sensitive to numerical changes in the parameter values. Our work offers a mathematical insight into how SARS-CoV-2 causes the disease.
摘要
2019冠状病毒病（COVID-19）现已成为全球大流行疾病。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是COVID-19的致病病原体。在此，我们研究了一个宿主内模型，该模型突出了效应T细胞对SARS-CoV-2的反应。具有病毒载量的唯一正平衡点的稳定性表明，病毒可能复制得足够快，以克服T细胞反应并导致感染。这种克服是分岔点，在该点附近， 的数量级可能对参数值的数值变化敏感。我们的工作为SARS-CoV-2如何引发疾病提供了数学见解。
相似文献
1
Stability analysis in COVID-19 within-host model with immune response.
Commun Nonlinear Sci Numer Simul. 2021 Apr;95:105584. doi: 10.1016/j.cnsns.2020.105584. Epub 2020 Nov 3.
2
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
3
SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Elife. 2020 May 26;9:e58603. doi: 10.7554/eLife.58603.
4
Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy.
Vaccines (Basel). 2022 Oct 31;10(11):1846. doi: 10.3390/vaccines10111846.
5
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
mBio. 2018 Oct 9;9(5):e01753-18. doi: 10.1128/mBio.01753-18.
6
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.
7
Global dynamics of SARS-CoV-2/cancer model with immune responses.
Appl Math Comput. 2021 Nov 1;408:126364. doi: 10.1016/j.amc.2021.126364. Epub 2021 May 12.
8
The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
J Virol. 2022 Jan 12;96(1):e0096421. doi: 10.1128/JVI.00964-21. Epub 2021 Oct 20.
9
Dynamical demeanour of SARS-CoV-2 virus undergoing immune response mechanism in COVID-19 pandemic.
Eur Phys J Spec Top. 2022;231(18-20):3357-3370. doi: 10.1140/epjs/s11734-022-00437-5. Epub 2022 Jan 20.
10
A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Arch Microbiol. 2021 Jul;203(5):1943-1951. doi: 10.1007/s00203-021-02265-y. Epub 2021 Mar 7.
引用本文的文献
1
A biomathematical model of SARS-CoV-2 in Syrian hamsters.
Sci Rep. 2024 Dec 18;14(1):30541. doi: 10.1038/s41598-024-80498-9.
2
Stability of a discrete HTLV-1/SARS-CoV-2 dual infection model.
Heliyon. 2024 Mar 18;10(7):e28178. doi: 10.1016/j.heliyon.2024.e28178. eCollection 2024 Apr 15.
3
Vaccine and antiviral drug promise for preventing post-acute sequelae of COVID-19, and their combination for its treatment.
Front Immunol. 2024 Aug 9;15:1329162. doi: 10.3389/fimmu.2024.1329162. eCollection 2024.
4
Model predictive control for optimal social distancing in a type SIR-switched model.
IFAC Pap OnLine. 2021;54(15):251-256. doi: 10.1016/j.ifacol.2021.10.264. Epub 2021 Nov 2.
5
COVID-19 dynamics and immune response: Linking within-host and between-host dynamics.
Chaos Solitons Fractals. 2023 Jun 26:113722. doi: 10.1016/j.chaos.2023.113722.
6
Confinement tonicity on epidemic spreading.
J Math Biol. 2024 Mar 22;88(4):46. doi: 10.1007/s00285-024-02064-1.
7
Aging, Inflammation, and Comorbidity in Cancers-A General In Silico Study Exemplified by Myeloproliferative Malignancies.
Cancers (Basel). 2023 Sep 29;15(19):4806. doi: 10.3390/cancers15194806.
8
Topological data analysis of antibody dynamics of severe and non-severe patients with COVID-19.
Math Biosci. 2023 Jul;361:109011. doi: 10.1016/j.mbs.2023.109011. Epub 2023 May 5.
9
Stability of a delayed SARS-CoV-2 reactivation model with logistic growth and adaptive immune response.
Physica A. 2023 Apr 15;616:128604. doi: 10.1016/j.physa.2023.128604. Epub 2023 Feb 24.
10
Stability analysis of within-host SARS-CoV-2/HIV coinfection model.
Math Methods Appl Sci. 2022 Jun 3. doi: 10.1002/mma.8457.
本文引用的文献
1
In-host Mathematical Modelling of COVID-19 in Humans.
Annu Rev Control. 2020;50:448-456. doi: 10.1016/j.arcontrol.2020.09.006. Epub 2020 Sep 30.
2
The within-host viral kinetics of SARS-CoV-2.
Math Biosci Eng. 2020 Mar 26;17(4):2853-2861. doi: 10.3934/mbe.2020159.
3
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.
Sci Rep. 2020 Aug 4;10(1):13093. doi: 10.1038/s41598-020-70143-6.
4
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
5
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
6
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
7
SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.
Geroscience. 2020 Apr;42(2):505-514. doi: 10.1007/s11357-020-00186-0. Epub 2020 Apr 10.
8
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
9
Virological assessment of hospitalized patients with COVID-2019.
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
10
Progress and Prospects on Vaccine Development against SARS-CoV-2.
Vaccines (Basel). 2020 Mar 29;8(2):153. doi: 10.3390/vaccines8020153.
Zotero 插件